Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Res. 2023 10 02; 25(1):112.
-
Bulen BJ, Khazanov NA, Hovelson DH, Lamb LE, Matrana M, Burkard ME, Yang ES, Edenfield WJ, Claire Dees E, Onitilo AA, Buchschacher GL, Miller AM, Parsons BM, Wassenaar TR, Suga JM, Siegel RD, Irvin W, Nair S, Slim JN, Misleh J, Khatri J, Masters GA, Thomas S, Safa MM, Anderson DM, Mowers J, Dusenbery AC, Drewery S, Plouffe K, Reeder T, Vakil H, Patrias L, Falzetta A, Hamilton R, Kwiatkowski K, Johnson DB, Rhodes DR, Tomlins SA. Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. Cancer Res Commun. 2023 07; 3(7):1335-1349.
-
Yi M, Zhan T, Peck AR, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Sun Y, Rui H, Chervoneva I. Selection of optimal quantile protein biomarkers based on cell-level immunohistochemistry data. BMC Bioinformatics. 2023 Jul 22; 24(1):298.
-
Nanou A, Miao J, Coumans FAW, Dolce EM, Darga E, Barlow W, Smerage JB, Paoletti C, Godwin AK, Pusztai L, Sharma P, Thompson A, Hortobagyi GN, Terstappen LWMM, Hayes DF. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. JCO Precis Oncol. 2023 01; 7:e2200372.
-
Benini S, Gamberi G, Cocchi S, Magagnoli G, Fortunato AR, Sciulli E, Righi A, Gambarotti M. The Efficacy of Molecular Analysis in the Diagnosis of Bone and Soft Tissue Sarcoma: A 15-Year Mono-Institutional Study. Int J Mol Sci. 2022 Dec 30; 24(1).
-
Chen CG, Aldape K, Dhillon KS, Laske DW, Abdullaev Z, Marotta DA, Miettinen M, Curtis MT. DNA methylation profiling and histologic analysis of sellar TTF-1-positive papillary epithelial tumor supports a novel CNS entity. J Neuropathol Exp Neurol. 2022 12 19; 82(1):96-98.
-
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res. 2022 12 16; 24(1):90.
-
Hayes DF, Sauerbrei W, McShane LM. REMARK guidelines for tumour biomarker study reporting: a remarkable history. Br J Cancer. 2023 Feb; 128(3):443-445.
-
Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nat Commun. 2022 12 05; 13(1):7495.
-
Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454.